https://www.oncologynurseadvisor.com Thu, 04 Jan 2024 20:08:14 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png https://www.oncologynurseadvisor.com 32 32 https://www.oncologynurseadvisor.com/reports/venetoclax-ibrutinib-mcl-new-standard/ Wed, 27 Dec 2023 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=114940 Adding venetoclax to treatment with ibrutinib improved outcomes in patients with relapsed or refractory MCL in a phase 3 trial.]]> https://www.oncologynurseadvisor.com/home/cancer-types/ovarian-cancer/fewer-cycles-of-neoadjuvant-chemotherapy-linked-to-better-survival-in-ovarian-cancer/ Mon, 27 Nov 2023 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=114258 Receiving fewer cycles of neoadjuvant chemotherapy and undergoing surgery earlier is associated with better survival outcomes in patients with advanced epithelial ovarian cancer, a meta-analysis suggests.]]> https://www.oncologynurseadvisor.com/home/cancer-types/breast-cancer/vitamin-d-insufficiency-linked-to-increased-risk-of-cipn-in-breast-cancer/ Tue, 21 Nov 2023 15:40:00 +0000 https://www.oncologynurseadvisor.com/?p=114132 Vitamin D insufficiency may increase the risk of chemotherapy-induced peripheral neuropathy, according to researchers.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/pembrolizumab-chemo-improves-survival-advanced-pleural-mesothelioma/ Fri, 17 Nov 2023 15:50:00 +0000 https://www.oncologynurseadvisor.com/?p=114153 Pembrolizumab plus platinum-pemetrexed chemotherapy may be a new treatment option for patients with advanced pleural mesothelioma.]]> https://www.oncologynurseadvisor.com/home/cancer-types/gastrointestinal-cancer/camrelizumab-plus-apatinib-and-haic-appears-safe-effective-in-advanced-hcc/ Thu, 16 Nov 2023 15:30:00 +0000 https://www.oncologynurseadvisor.com/?p=114075 The combination of camrelizumab, apatinib, and HAIC demonstrated “encouraging” results in patients with advanced HCC, according to researchers.]]> https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/lobbying-data-show-increased-spending-by-oncology-organizations-cancer-hospitals/ Tue, 14 Nov 2023 15:30:00 +0000 https://www.oncologynurseadvisor.com/?p=113920 Some oncology lobbying spending has increased in recent years, while other spending has remained stable.]]> https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/health-insurance-financial-issues-are-primary-legal-barriers-for-cancer-patients/ Mon, 13 Nov 2023 15:30:00 +0000 https://www.oncologynurseadvisor.com/?p=113964 The most common legal barriers cancer patients face are related to health insurance, financial issues, and disability, a new study suggests.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/adding-chemotherapy-to-osimertinib-improves-pfs-in-egfr-mutant-advanced-nsclc/ Wed, 27 Sep 2023 14:30:00 +0000 https://www.oncologynurseadvisor.com/?p=110917 Osimertinib and chemotherapy is more effective than osimertinib alone as first-line treatment for patients with EGFR-mutant, advanced NSCLC, phase 3 data suggest.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/incidence-lung-cancer-subtypes-varies-region/ Tue, 19 Sep 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=110684 Incidence rates of lung cancer subtypes vary across global regions, data suggest.]]> https://www.oncologynurseadvisor.com/home/cancer-types/breast-cancer/burden-of-high-deductible-health-plans-may-delay-breast-cancer-diagnosis/ Wed, 13 Sep 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=110332 The cost-sharing burden of high-deductible health plans may delay breast cancer diagnosis, according to researchers.]]>